Delivery Order SPE2DB24D9113-SPE2DB25FEQBU
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 10, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract ceiling value is $38,376.87, with an ultimate completion date of September 11, 2025. This delivery order carries no set-aside designation and represents a direct fulfillment order under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,622.72 by the Defense Logistics Agency (DLA) on June 5, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract, which carries no set-aside designation, is scheduled for ultimate completion by June 6, 2025, with performance taking place at the vendor's Park Ridge facility. This delivery order was...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,311.35 by the Defense Logistics Agency (DLA) on July 31, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The delivery order carries an ultimate completion date of August 1, 2025, and was issued without set-aside designation. This award represents a single delivery order issued under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on August 5, 2025, for the supply of Xtandi 40 mg tablets (120-count packages). The contract, valued at $8,339.18 with an ultimate completion date of August 6, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $25,868.10 by the Defense Logistics Agency for the supply of Xtandi 40 mg capsules (120-count units). The contract is firm fixed-price with an ultimate completion date of September 2, 2025, and carries no set-aside designation. This delivery order represents one of numerous pharmaceutical supply contracts issued to DMS Pharmaceutical Group...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on August 8, 2025, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, valued at $8,622.72 with an ultimate completion date of August 11, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 11, 2025, for the supply of Xtandi 40 mg tablets (120-count units). The contract, valued at $8,339.18 with a completion date of September 12, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on September 2, 2025, for the supply of Xtandi 40 mg capsules (120-count) valued at $4,311.35. This firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency responsible for providing logistics support to the Department of Defense. The award carries no set-aside designation, and the contract specifies a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,311.35 by the Defense Logistics Agency on September 8, 2025, for the supply of Xtandi 40 mg capsules (quantity: 120). This firm fixed-price delivery order, which is scheduled for completion by September 9, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $499.99...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $21,556.75 for Xtandi 40mg capsules (120-count units) on June 25, 2025, with an ultimate completion date of June 26, 2025. The award carries no set-aside designation and is funded by the Defense Logistics Agency's Medical Supply Chain division. This delivery order falls under DMS Pharmaceutical Group's larger single-award...
- SPE2DB24D9113Indefinite Delivery Contract
- SPE2DB24D9113-SPE2DB25FEQBUDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,311.35 by the Defense Logistics Agency (DLA) on July 14, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of July 15, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting Department of Defense healthcare facilities worldwide. Xtandi is a prescription oncology medication used in the treatment of prostate cancer, reflecting DMS Pharmaceutical Group's established role as a critical supplier of specialty pharmaceuticals to military health systems. The company's extensive federal contract portfolio demonstrates consistent success in delivering branded and generic prescription drugs, biologics, and medical consumables to DLA and other federal healthcare agencies. This delivery order represents a routine procurement under the broader SPE2DB framework, leveraging the established master contract terms and conditions to rapidly fulfill specific pharmaceutical supply requirements across the military healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 7/14/25 |